BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 18, 2024
See today's BioWorld
Home
» Transgene seeks new taker for TG4010 as Novartis opts out
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Transgene seeks new taker for TG4010 as Novartis opts out
April 30, 2014
By
Cormac Sheridan
No Comments
Shares in Transgene SA dropped 15 percent Tuesday as Novartis AG decided not to trigger an option on its therapeutic vaccine TG4010, which is currently undergoing a phase IIb/III trial in non-small-cell lung cancer (NSCLC).
BioWorld